COMPARISON OF THE EFFICACY AND SAFETY OF INNOVATOR RITUXIMAB AND RITUXIMAB BIOSIMILAR

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HPS-055
• By: ISEZAKI, Tatsuya (Japan)
• Co-author(s): Tatsuya Isezaki: Department of Pharmacy, Kameda medical center, Chiba, Japan
  Keiko Miyagawa: Department of Pharmacy, Kameda medical center, Chiba, Japan
  Kentaro Narita: Department of Hematology, Kameda medical center, Chiba, Japan
  Ryohkan Funakoshi: Department of Pharmacy, Kameda medical center, Chiba, Japan
  
• Abstract:

  Background

  Biosimilars are products that are equivalent to original bio-pharmaceuticals. The use of biosimilars increases medical access to useful treatments, improves the quality of treatment, and reduces costs. The inclusion criteria for the rituximab biosimilar clinical trials were limited to patients with follicular lymphoma, and an analysis of ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login